CTNM
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ · USHealthcareBiotechnology
$13.53-4.92%
Price as of Jul 20, 2026
CTNM valuation
Contineum Therapeutics, Inc. Class A Common Stock valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 89.53x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.02x
- Price / sales
- —
- Price / cash flow
- -8.85x
Enterprise value
- Enterprise value
- $266.5M
- EV / sales
- —
- EV / EBITDA
- -4.59x
- EV / EBIT
- -3.99x
- Market cap
- $505.8M
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.